logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
23/03/2026
British Prime Minister Stammer: We need to ease the situation.
Latest
4 m ago
Guangzhi Technology: Net loss of 33.1997 million yuan in 2025.
4 m ago
The Turkish bank index fell by 6.8%, reaching its lowest level since November 26 of last year.
6 m ago
The International Atomic Energy Agency reaffirms that no military action should jeopardize the safety of nuclear power plants.
6 m ago
Zhongyan Dadi: Abandoning the winning bid for the nuclear power project due to major adjustments in the implementation plan.
7 m ago
The announcement of the Group of Chinese Drug Group: The Group has developed Aprepitant Injection (4.4ml:32mg), which has obtained the drug registration approval from the National Medical Products Administration of the People's Republic of China. This product is a new generation NK-1 receptor antagonist, a submicellar injection that can selectively bind to NK-1 receptors in the brain and antagonize substance P effectively to prevent acute and delayed vomiting. This product is suitable for preventing postoperative nausea and vomiting (PONV) in adults. Compared to traditional forms of Aprepitant, this product has a rapid onset of action, significantly improves patient compliance, and effectively reduces the occurrence of allergic reactions in clinical use. It provides a better medication choice for the prevention of postoperative nausea and vomiting in adults.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.